Aptose Biosciences (APS) Competitors

ProMetic Life Sciences (TSE:PLI) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, community ranking, media sentiment and valuation.

Does the media prefer PLI or APS?

In the previous week, Aptose Biosciences had 1 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 1 mentions for Aptose Biosciences and 0 mentions for ProMetic Life Sciences. Aptose Biosciences' average media sentiment score of 0.75 beat ProMetic Life Sciences' score of 0.00 indicating that Aptose Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ProMetic Life Sciences	Neutral
Aptose Biosciences	Positive

Do insiders and institutionals hold more shares of PLI or APS?

15.1% of Aptose Biosciences shares are owned by institutional investors. 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is PLI or APS more profitable?

Aptose Biosciences' return on equity of 1,017.48% beat ProMetic Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	N/A	N/A	N/A
Aptose Biosciences	N/A	1,017.48%	-136.29%

Which has preferable valuation and earnings, PLI or APS?

Aptose Biosciences has lower revenue, but higher earnings than ProMetic Life Sciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	C$39.91M	0.00	-C$1.47B	-C$63.06	N/A
Aptose Biosciences	N/A	N/A	-C$154.69M	-C$5.02	-0.66

Does the MarketBeat Community favor PLI or APS?

ProMetic Life Sciences received 229 more outperform votes than Aptose Biosciences when rated by MarketBeat users. However, 72.20% of users gave Aptose Biosciences an outperform vote while only 67.69% of users gave ProMetic Life Sciences an outperform vote.

Company	Underperform	Outperform
ProMetic Life Sciences	Outperform Votes 442 67.69%	Underperform Votes 211 32.31%
Aptose Biosciences	Outperform Votes 213 72.20%	Underperform Votes 82 27.80%

Do analysts rate PLI or APS?

Given ProMetic Life Sciences' higher possible upside, research analysts clearly believe ProMetic Life Sciences is more favorable than Aptose Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProMetic Life Sciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aptose Biosciences	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	4.00

Summary

Aptose Biosciences beats ProMetic Life Sciences on 10 of the 15 factors compared between the two stocks.